Edinburgh, UK – 23/05/23 – Nodus Oncology, an emerging biotech company which is focused on developing first and best-in-class molecules inhibiting novel DDR targets, announces the appointment of Prof. Keith Caldecott as scientific advisory board (SAB) member.
“We are delighted to welcome to welcome Keith in our SAB” said Ian Waddell, CEO of Nodus Oncology. “Keith’s expertise is a great addition to complement the expertise of our SAB”.
This newly formed advisory board includes the following scientific and preclinical experts:
- Keith Caldecott, FRS FMedSci. Keith is an elected Fellow of the Royal Society, Academy of Medical Sciences, and EMBO, and is a Professor of Genome Stability at the University of Sussex (UK). Keith developed his interest in DDR during his PhD at the Medical Research Council’s National Institute for Medical Research in London, in Penny Jeggo’s lab. His interest in DNA repair continued during postdoctoral fellowships in California with Larry Thompson at the Lawrence Livermore National Laboratory, and with Tomas Lindahl FRS at the Cancer Research UK's laboratory at Clare Hall, London. In 1995, Keith established his own laboratory at the University of Manchester, and in 2002 moved to the Genome Damage and Stability Centre (GDSC); a multi-disciplinary centre-of-excellence funded jointly by the MRC and the University of Sussex. The Caldecott lab is focussed on identifying new human DNA repair genes and unravelling the link between defects in DNA strand break repair and human genetic disease.
